Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TUKIS: Tenecteplase Plus Urinary Kallidinogenase for Acute Ischemic Stroke
NCT07283159Phase 2Recruiting
- Sponsor
- General Hospital of the Northern Theater Command
- Start
- Jan 2026
- Primary completion
- Sep 2027
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of human urinary kallidinogenase + Shuxuening injection in ischemic stroke, sponsored by General Hospital of the Northern Theater Command. Started Jan 2026; status: recruiting.
02
Drugs
human urinary kallidinogenase + Shuxuening injection
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT07283159.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07283159.